biostudies-literatureBennani NNBristol-Myers SquibbMayo ClinicNCI NIH HHSPaul Calabresi Program in Translational Research at Mayo ClinicT-Cell Leukemia Lymphoma FoundationLeukemia and Lymphoma Societye004984https://www.ebi.ac.uk/biostudies/studies/S-EPMC9234908biostudies-literatureUnknown10(6)Peripheral T-cell lymphomas (PTCL), a heterogeneous group of mature aggressive non-Hodgkin's lymphomas, carry a worse prognosis for most subtypes when compared with their B-cell counterparts. Despite recent approval of newer therapies, the outlook for patients with relapsed/refractory (RR) PTCL remains poor and new treatment strategies are clearly needed. Targeting the profoundly immunosuppressive tumor microenvironment in PTCL is one such approach. To determine whether immune checkpoint blockade targeting program death receptor 1 would be effective in PTCL, we conducted an investigator-initiated phase 2 prospective study of single-agent nivolumab for RR PTCL. We report here results of the pre-specified interim analysis.<h4>Methods</h4>The primary objective was to assess the overall responJournal for immunotherapy of cancerNivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.PMC9234908Translational Research Program (TRP) / TRP-6574-19K-12 Calabresi Award / 2K12CA090628-21K12 CA090628CATALYSTAnsell SMFeldman ALBennani NNWitzig TKim HJMicallef INPederson LDAtherton PJThanarajasingam GNowakowski GSfalseNivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.Peripheral T-cell lymphomas (PTCL), a heterogeneous group of mature aggressive non-Hodgkin's lymphomas, carry a worse prognosis for most subtypes when compared with their B-cell counterparts. Despite recent approval of newer therapies, the outlook for patients with relapsed/refractory (RR) PTCL remains poor and new treatment strategies are clearly needed. Targeting the profoundly immunosuppressive tumor microenvironment in PTCL is one such approach. To determine whether immune checkpoint blockade targeting program death receptor 1 would be effective in PTCL, we conducted an investigator-initiated phase 2 prospective study of single-agent nivolumab for RR PTCL. We report here results of the pre-specified interim analysis.<h4>Methods</h4>The primary objective was to assess the overall respon2022-01-01T00:00:00Z2022 Jun2026-06-15T06:13:37.65Z2026-06-15T03:08:49.723ZS-EPMC92349083575041910.1136/jitc-2022-004984